Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 157

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 157
---
irement” (as 
 defined in the applicable Enfusion RSU award agreement).                                                                                                                                                                               |

| (2) | Enfusion RSUs held by Enfusion directors will fully accelerate and vest at the Closing of the Transactions                                                                 
 pursuant to the Enfusion Non-Employee Director Compensation Policy, and be converted into the right of each holder to receive the Merger Consideration as described above. |

| (3) | In accordance with Enfusion PSU award agreements, 250,000 Enfusion PSUs held by Mr. Movchan will be                                                                                                                                                     
 converted into Enfusion RSUs as of the Effective Time and will be treated under the Merger Agreement in accordance with the treatment described above for Enfusion RSUs. In accordance with Enfusion PSU award agreements, all other Enfusion PSUs will 
 be cancelled as of the Effective Time for no consideration.                                                                                                                                                                                             |

100

Transaction and Transition Bonuses In connection with the Transactions, each of Mr. Pawar, Ms. Bastone, Mr. Herring and Mr. Campobasso were granted cash transaction and transition bonuses equal to $400,000, $200,000, $400,000 and $380,000, respectively, subject to such Enfusion executive officer’s continued employment through the Closing of the Transactions. For Mr. Pawar, Ms. Bastone, Mr. Herring and Mr. Campobasso, they will be required to repay $280,000, $21,000, $42,000 and $266,000, respectively and in each case net of any taxes that they were required to pay in connection with such bonus, in the event that their employment is terminated following the Closing of the Transactions, and prior to December 31, 2025, by Enfusion or Clearwater with “cause” or by such Enfusion executive officer without “good reason” (as such terms are defined in the Severance Policy or, for Mr. Pawar, his employment agreement). Severance Payments Upon a Qualifying Termination Prior to or Following the Effective Time Executive Severance Policy Each of the Enfusion executive officers (other than Mr. Pawar) is eligible to receive severance benefits under the Severance Policy as “covered executives.” In the event that a covered executive’s employment is terminated by Enfusion or its successors (including Clearwater) without “cause” or by the covered executive’s resignation for “good reason” (as each term is defined in the Severance Policy), subject to the covered executive’s execution and non-revocation